Next-Generation Sequencing of 5′ Untranslated Region of Hepatitis C Virus in Search of Minor Viral Variant in a Patient Who Revealed New Genotype While on Antiviral Treatment

Author(s):  
Kamila Caraballo Cortes ◽  
Iwona Bukowska-Ośko ◽  
Agnieszka Pawełczyk ◽  
Karol Perlejewski ◽  
Rafał Płoski ◽  
...  
PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0150311 ◽  
Author(s):  
Kamila Caraballo Cortes ◽  
Osvaldo Zagordi ◽  
Joanna Jabłońska ◽  
Agnieszka Pawełczyk ◽  
Natalia Kubisa ◽  
...  

2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Hany K. Soliman ◽  
Mohamed Abouelhoda ◽  
Mahmoud N. El Rouby ◽  
Ola S. Ahmed ◽  
G. Esmat ◽  
...  

Abstract Background Human pegivirus (HPgV) is structurally similar to hepatitis C virus (HCV) and was discovered 20 years ago. Its distribution, natural history and exact rule of this viral group in human hosts remain unclear. Our aim was to determine, by deep next-generation sequencing (NGS), the entire genome sequence of HPgV that was discovered in an Egyptian patient while analyzing HCV sequence from the same patient. We also inspected whether the co-infection of HCV and HPgV will affect the patient response to HCV viral treatment. To the best of our knowledge, this is the first report for a newly isolated HPgV in an Egyptian patient who is co-infected with HCV. Case presentation The deep Next Generation Sequencing (NGS) technique was used to detect HCV sequence in hepatitis C patient’s plasma. The results revealed the presence of HPgV with HCV. This co-infection was confirmed using conventional PCR of the HPgV 5′ untranslated region. The patient was then subjected to direct-acting-antiviral treatment (DAA). At the end of the treatment, the patient showed a good response to the HCV treatment (i.e., no HCV-RNA was detected in the plasma), while the HPgV-RNA was still detected. Sequence alignment and phylogenetic analyses demonstrated that the detected HPgV was a novel isolate and was not previously published. Conclusion We report a new variant of HPgV in a patient suffering from hepatitis C viral infection.


2018 ◽  
Vol 108 ◽  
pp. 26-31 ◽  
Author(s):  
Sana Saleem ◽  
Amjad Ali ◽  
Bushra Khubaib ◽  
Madiha Akram ◽  
Zareen Fatima ◽  
...  

2019 ◽  
Vol 56 (6) ◽  
pp. 420-434 ◽  
Author(s):  
Lize Cuypers ◽  
Marijn Thijssen ◽  
Arash Shakibzadeh ◽  
Farzaneh Sabahi ◽  
Mehrdad Ravanshad ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0145530 ◽  
Author(s):  
Joseph C. Forbi ◽  
Jennifer E. Layden ◽  
Richard O. Phillips ◽  
Nallely Mora ◽  
Guo-liang Xia ◽  
...  

2020 ◽  
Vol 222 (3) ◽  
pp. 488-498 ◽  
Author(s):  
Matthew J Akiyama ◽  
Daniel Lipsey ◽  
Lilia Ganova-Raeva ◽  
Lili T Punkova ◽  
Linda Agyemang ◽  
...  

Abstract Background Understanding hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is essential for HCV elimination. We aimed to differentiate reinfections from treatment failures and to identify transmission linkages and associated factors in a cohort of PWID receiving opioid agonist therapy (OAT). Methods We analyzed baseline and follow-up specimens from 150 PWID from 3 OAT clinics in the Bronx, New York. Next-generation sequencing data from the hypervariable region 1 of HCV were analyzed using Global Hepatitis Outbreak and Surveillance Technology. Results There were 3 transmission linkages between study participants. Sustained virologic response (SVR) was not achieved in 9 participants: 7 had follow-up specimens with similar sequences to baseline, and 2 died. In 4 additional participants, SVR was achieved but the participants were viremic at later follow-up: 2 were reinfected with different strains, 1 had a late treatment failure, and 1 was transiently viremic 17 months after treatment. All transmission linkages were from the same OAT clinic and involved spousal or common-law partnerships. Conclusion This study highlights the use of next-generation sequencing as an important tool for identifying viral transmission and to help distinguish relapse and reinfection among PWID. Results reinforce the need for harm reduction interventions among couples and those who report ongoing risk factors after SVR.


PLoS ONE ◽  
2017 ◽  
Vol 12 (7) ◽  
pp. e0181273 ◽  
Author(s):  
Evelyn Stelzl ◽  
Bernhard Haas ◽  
Bernd Bauer ◽  
Sherry Zhang ◽  
Ellen H. Fiss ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document